FLT3 and melanoma: We also analyzed flow cytometry data from a second CITN trial: CITN-07 (NCT02129075, see supplemental experimental procedures A.1 for trial data), a randomized phase II trial studying immune responses against a DEC-205/NY-ESO-1 fusion protein (CDX-1401) and a neoantigen-based melanoma vaccine plus poly-ICLC when delivered with or without recombinant FLT3 ligand (CDX-301) in treating patients with stage IIB to stage IV melanoma.